Crystallographic Characterization of Amodiaquine Hydrochloride as an Antimalarial Active Pharmaceutical Ingredient

Timbul Partogi Haposan Simorangkir, Giyantolin Giyantolin

Abstract


Solid-state properties of active pharmaceutical ingredients are important in dosage-form development because phase transformation, hydrate or solvate formation, and crystal habit modification can influence manufacturing performance and physicochemical properties. Amodiaquine hydrochloride (AQ) is an antimalarial active pharmaceutical ingredient used in artemisinin-based combination therapy and is known to occur as a hydrated crystalline form. This study evaluated the solid-state characteristics of AQ and the effects of recrystallization, heating, and milling on its crystal structure, crystallinity, thermal behavior, and morphology. AQ samples before and after treatment were characterized using powder X-ray diffraction (PXRD), thermal analysis, Fourier-transform infrared spectroscopy (FT-IR), hot-stage/polarized-light microscopy, scanning electron microscopy (SEM), and single-crystal X-ray diffraction. Recrystallization from methanol, chloroform, and acetone did not produce new PXRD peaks or meaningful changes in crystal habit. Heating at 170 °C for 1 hour produced thermal changes consistent with dehydration, without evidence of polymorphic conversion. Milling for 10, 30, and 60 minutes reduced crystallinity and thermal enthalpy, indicating lattice defects rather than formation of a new polymorph. FT-IR spectra retained the main absorption bands after thermal and mechanical treatments, suggesting that no major spectroscopic changes indicating chemical degradation were detected. Single-crystal analysis confirmed a monoclinic crystal system with space group P21/c, consistent with amodiaquine hydrochloride dihydrate. Overall, AQ maintained the same crystalline phase under the evaluated recrystallization, heating, and milling conditions, although hydration-state changes after heating should be interpreted cautiously.

Keywords


Amodiaquine hydrochloride; Solid-state characterization; PXRD; Thermal analysis; FT-IR; Crystal habit; Antimalarial API.

Full Text:

PDF

References


Y. Gui, “Solid Form Screenings in Pharmaceutical Development: a Perspective on Current Practices.,” Pharm. Res., vol. 40, no. 10, pp. 2347–2354, Oct. 2023, doi: 10.1007/s11095-023-03573-2.

N. H. Ram et al., “The impact of crystal habit on the pharmaceutical properties of active pharmaceutical ingredients,” CrystEngComm, vol. 27, no. 27, pp. 4614–4633, 2025, doi: 10.1039/D4CE01170H.

A. J. Cruz-Cabeza, P. R. Spackman, and A. V Hall, “The interplay between hydrogen bonds and stacking/T-type interactions in molecular cocrystals,” Commun. Chem., vol. 7, no. 1, p. 284, 2024, doi: 10.1038/s42004-024-01380-3.

S. Zhou, T. Yang, C. Qian, F. Wu, Y. Hong, and X. Lin, “An update on solid-state form, crystal modification and transition issues related to tablet manufacturing,” J. Drug Deliv. Sci. Technol., vol. 100, p. 106135, 2024, doi: https://doi.org/10.1016/j.jddst.2024.106135.

M. Guerain and J.-F. Willart, “Polymorphic Transformations of Pharmaceutical Materials Induced by Mechanical Milling: A Review,” Pharmaceutics, vol. 17, no. 7. p. 946, 2025. doi: 10.3390/pharmaceutics17070946.

U. Kestur, A. Patel, S. Badawy, N. Mathias, and L. Zhang, “Strategies for Managing Solid Form Transformation Risk in Drug Product,” J. Pharm. Sci., vol. 112, no. 4, pp. 909–921, Apr. 2023, doi: 10.1016/j.xphs.2022.12.002.

World Health Organization, WHO guidelines for malaria. Geneva: World Health Organization, 2025.

W. Sirikun, J. Chatchawalsaisin, and N. Sutanthavibul, “Solid-State Characterization and Interconversion of Recrystallized Amodiaquine Dihydrochloride in Aliphatic Monohydric Alcohols.,” AAPS PharmSciTech, vol. 17, no. 2, pp. 427–435, Apr. 2016, doi: 10.1208/s12249-015-0355-4.

V. V Chernyshev, “Structural Characterization of Pharmaceutical Cocrystals with the Use of Laboratory X-ray Powder Diffraction Patterns,” Crystals, vol. 13, no. 4, 2023, doi: 10.3390/cryst13040640.

Y. Tao et al., “Advances in Quantitative Analytical Methods for Solid Drugs,” Crystals, vol. 15, no. 1. p. 38, 2025. doi: 10.3390/cryst15010038.

M. Singh, M. R. Dhondale, A. K. Agrawal, and D. Kumar, “Sonocrystallization approach in crystal habit modification for improving the pharmaceutical properties of Rivaroxaban,” Ultrason. Sonochem., vol. 131, p. 107921, 2026, doi: https://doi.org/10.1016/j.ultsonch.2026.107921.

I. Bade, D. Etit, and J. Y. Y. Heng, “The effect of solvents on crystal regeneration,” CrystEngComm, vol. 28, no. 2, 2026, doi: 10.1039/d5ce00353a.

D. Braga, L. Casali, and F. Grepioni, “The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?,” Int. J. Mol. Sci., vol. 23, no. 16, Aug. 2022, doi: 10.3390/ijms23169013.

J. Bernstein, “Polymorphism − A Perspective,” Cryst. Growth Des., vol. 11, no. 3, pp. 632–650, Mar. 2011, doi: 10.1021/cg1013335.

M. Moret and A. Gavezzotti, “The crystalline state of rubrene materials : analysis of morphologies †,” New J. Chem, vol. 46, pp. 7626–7637, 2022, doi: 10.1039/d2nj00861k.

K. D. Sawant and T. A. Naik, “Necessity of Establishing Chemical Integrity of Polymorphs of Drug Substance Using a Combination of NMR, HPLC, Elemental Analysis, and Solid-State Characterization Techniques: Case Studies,” Org. Process Res. Dev., vol. 17, no. 3, pp. 519–532, Mar. 2013, doi: 10.1021/op300229k.




DOI: https://doi.org/10.37311/ijpe.v6i2.39966

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 Timbul Partogi Haposan Simorangkir, Giyantolin Giyantolin

Creative Commons License
Indonesian Journal of Pharmaceutical Education is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.